Improving HIV Prevention for People Who Inject Drugs on MOUD
Optimizing evidence-based HIV prevention targeting people who inject drugs on PrEP
This project aims to create better ways to help people who inject drugs who are also taking medication for opioid use disorder to prevent HIV and stick to their PrEP medication.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Storrs NIH-funded |
| Lab location | 1 site (Storrs-Mansfield, United States) |
| Project ID | NIH-11131160 on NIH RePORTER |
What this research studies
Many people who inject drugs experience challenges with memory, attention, and thinking, which can make it hard to understand and follow HIV prevention advice. This project is developing new approaches to help improve these thinking skills, making it easier for individuals to use information about preventing HIV. By focusing on areas like attention and memory, we hope to help people better understand and consistently take their PrEP medication. This could lead to a significant reduction in HIV risk for this group.
Who could benefit from this research
Good fit: Ideal candidates for this type of research would be people who inject drugs and are newly enrolled in medication for opioid use disorder.
Not a fit: Patients who do not inject drugs or are not on medication for opioid use disorder may not directly benefit from this specific intervention.
Why it matters
Potential benefit: If successful, this work could lead to more effective HIV prevention strategies and better PrEP adherence for people who inject drugs, ultimately reducing new HIV infections.
How similar studies have performed: While existing HIV prevention methods are evidence-based, this project builds on preliminary studies to address a known weakness in accommodating cognitive challenges, suggesting a novel refinement.
Where this research is happening
Storrs-Mansfield, United States
- University of Connecticut Storrs — Storrs-Mansfield, United States (Active)
Researchers
- Principal investigator: Copenhaver, Michael — University of Connecticut Storrs
- Study coordinator: Copenhaver, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.